REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Announces Proposed Public Offering

07 ديسمبر 2022 15:04:04 بحسب Nasdaq GlobeNewswire

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

07 ديسمبر 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

07 ديسمبر 2022 05:30:00 بحسب Nasdaq GlobeNewswire

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

23 نوفمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on December 7, 2022

22 نوفمبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

03 نوفمبر 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

02 نوفمبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

07 أكتوبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

04 أغسطس 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 أغسطس 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

03 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune to Present at the Jefferies Healthcare Conference

02 يونيو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 مايو 2022 16:15:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

19 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

30 مارس 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on March 30, 2022

21 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 فبراير 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

03 فبراير 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

31 يناير 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

10 يناير 2022 06:00:02 بحسب Nasdaq GlobeNewswire